Active Ingredient History
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV). Intracellularly, lamivudine is phosphorylated to its active 5′-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is inhibition of HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. The most common reported adverse reactions in adults are headache, nausea, malaise and fatigue. No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acidosis, Lactic (Phase 4)
Acquired Immunodeficiency Syndrome (Phase 4)
Aicardi Syndrome (Phase 2)
AIDS-Associated Nephropathy (Phase 3)
Allografts (Phase 4)
Alveolar Bone Loss (Phase 4)
Alzheimer Disease (Phase 1/Phase 2)
Amyotrophic Lateral Sclerosis (Phase 3)
Antiretroviral Therapy, Highly Active (Phase 4)
Art (Phase 3)
Arthralgia (Phase 3)
Atrophy (Phase 4)
Body Weight Changes (Phase 4)
Bone Diseases, Metabolic (Phase 2)
Breast Feeding (Phase 3)
Carcinoma, Hepatocellular (Phase 4)
Cardiovascular Diseases (Phase 4)
Central Nervous System Diseases (Phase 4)
Cognition Disorders (Phase 4)
Colorectal Neoplasms (Phase 2)
Dementia (Phase 4)
Diarrhea (Phase 3)
Drug Interactions (Phase 4)
Drug Resistance (Phase 4)
Drugs, Investigational (Phase 4)
Dyslipidemias (Phase 4)
Fasting (Phase 3)
Fibrosis (Phase 3)
Gender Dysphoria (Phase 1)
Glomerulonephritis (Phase 2)
Glucose Metabolism Disorders (Phase 4)
Gout (Phase 2)
Healthy Volunteers (Phase 1)
Hemophilia A (Phase 4)
Hepatitis (Phase 3)
Hepatitis B (Phase 4)
Hepatitis B virus (Phase 4)
Hepatitis C (Phase 4)
Hepatitis, Chronic (Phase 4)
Hepatitis D, Chronic (Phase 2)
Herpesvirus 8, Human (Phase 4)
HIV (Phase 4)
HIV-1 (Phase 4)
HIV-Associated Lipodystrophy Syndrome (Phase 4)
HIV Seropositivity (Phase 3)
Hypercholesterolemia (Phase 4)
Infections ()
Lipodystrophy (Phase 4)
Liver Cirrhosis (Phase 1/Phase 2)
Liver Cirrhosis, Biliary (Phase 2/Phase 3)
Liver Diseases (Phase 4)
Liver Failure (Phase 1/Phase 2)
Liver Neoplasms (Phase 4)
Lung Diseases (Phase 1)
Lymphoma (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Malaria (Phase 3)
Malnutrition (Phase 4)
Medication Adherence (Early Phase 1)
Metabolic Diseases (Phase 4)
Metabolic Syndrome (Phase 3)
Minority Health (Phase 3)
Neoplasms (Phase 3)
Obesity (Phase 4)
Organ Transplantation (Phase 4)
Osteoporosis (Phase 4)
Paraparesis, Tropical Spastic (Phase 2/Phase 3)
Patient Compliance (Phase 4)
Persistent Infection (Phase 4)
Polyarteritis Nodosa (Phase 2)
Pregnancy (Phase 3)
Pregnancy Complications (Phase 4)
Proteinuria (Phase 4)
Recurrence (Phase 4)
Renal Insufficiency (Phase 4)
Respiratory Tract Infections (Phase 1/Phase 2)
Retinal Detachment (Early Phase 1)
Retinal Diseases (Early Phase 1)
Sarcoma, Kaposi (Phase 4)
Small Cell Lung Carcinoma (Phase 2)
Transgender Persons (Phase 1)
Tuberculosis (Phase 4)
Tuberculosis, Multidrug-Resistant (Phase 1)
Tuberculosis, Pulmonary (Phase 1)
Viremia (Phase 4)
Weight Gain (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
